Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
NCT05963386
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Refractory Solid Tumor
Interventions
DRUG:
177Lu-DOTA-EB-FAPI radionuclide therapy
Sponsor
The First Affiliated Hospital of Xiamen University